Scholarlink

<p>Herpes simplex virus type 1 (HSV-1) is a highly prevalent viral infection with limited medications. Thus, search for safe and effective alternative treatments is urgently needed. <i>Peganum harmala</i> L. (<i>P. harmala</i>) praised with antiviral potential may afford a decent option against HSV-1. This study creatively integrated network pharmacology and nanoscience to objectively disclose the efficacy mechanism of <i>P. harmala</i> bioactive compounds and augment the antiviral potential of <i>P. harmala</i> against HSV-1 via nanotechnology. Network pharmacology analysis revealed MAPK 1, SRC, EGFR and JAK1 as the top putative HSV-1 genes highly enriched in MAPK, PI3K-Akt, and JAK-STAT signalling pathways and primarily associated with the efficacy mechanism of <i>P. harmala</i> bioactive compounds against HSV-1. Complementarily, four <i>P. harmala</i> nano-formulations were established, monitored using different pharmaceutical scores, and assessed against HSV-1 using plaque reduction assay. Experimentally speaking, <i>P. harmala</i>-CS-ZnO NPs showed higher zeta (+ 40.8) with particle-size (73.06&#xa0;nm), higher entrapment (81.7%) with loading-capacity (6.8%), sustained release reaching 50.5% after 24&#xa0;h and demonstrated the most promising observation against HSV-1, with viral inhibition of 54.1% which is double the effect of crude extract alone with acceptable cytotoxicity (CC<sub>50</sub> = 271.4&#xa0;µg/ml). This enhanced effect is possibly due to the synergistic antiviral properties of <i>P. harmala</i> bioactive compounds, chitosan, and zinc oxide nanoparticles. This complex between the ingredients chemically detected by FT-IR analysis also improved stability, cellular uptake, viral inhibition, and bioavailability. Our findings offer a solid basis for more extensive and rational clinical integration of <i>P. harmala</i> in the pharmaceutical industry to rectify human herpes viruses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of Peganum harmala L. leaves extract nanoformulations against herpes simplex virus type 1 guided by network pharmacology analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Basant A. Abou-Taleb,
  • Aya M. Elbanan,
  • Hala M. Hammoda,
  • Ibrahim A. Abdelwahab,
  • Mohamed M. Mohyeldin,
  • Dina S. Ghallab

摘要

Herpes simplex virus type 1 (HSV-1) is a highly prevalent viral infection with limited medications. Thus, search for safe and effective alternative treatments is urgently needed. Peganum harmala L. (P. harmala) praised with antiviral potential may afford a decent option against HSV-1. This study creatively integrated network pharmacology and nanoscience to objectively disclose the efficacy mechanism of P. harmala bioactive compounds and augment the antiviral potential of P. harmala against HSV-1 via nanotechnology. Network pharmacology analysis revealed MAPK 1, SRC, EGFR and JAK1 as the top putative HSV-1 genes highly enriched in MAPK, PI3K-Akt, and JAK-STAT signalling pathways and primarily associated with the efficacy mechanism of P. harmala bioactive compounds against HSV-1. Complementarily, four P. harmala nano-formulations were established, monitored using different pharmaceutical scores, and assessed against HSV-1 using plaque reduction assay. Experimentally speaking, P. harmala-CS-ZnO NPs showed higher zeta (+ 40.8) with particle-size (73.06 nm), higher entrapment (81.7%) with loading-capacity (6.8%), sustained release reaching 50.5% after 24 h and demonstrated the most promising observation against HSV-1, with viral inhibition of 54.1% which is double the effect of crude extract alone with acceptable cytotoxicity (CC50 = 271.4 µg/ml). This enhanced effect is possibly due to the synergistic antiviral properties of P. harmala bioactive compounds, chitosan, and zinc oxide nanoparticles. This complex between the ingredients chemically detected by FT-IR analysis also improved stability, cellular uptake, viral inhibition, and bioavailability. Our findings offer a solid basis for more extensive and rational clinical integration of P. harmala in the pharmaceutical industry to rectify human herpes viruses.